×
OncoCyte Operating Expenses 2014-2024 | OCX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OncoCyte operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
OncoCyte Operating Expenses 2014-2024 | OCX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OncoCyte operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Elevance Health (ELV)
$91.4B
Cencora (COR)
$47.5B
DiDi Global (DIDIY)
$23.3B
Natera (NTRA)
$21.4B
ICON (ICLR)
$16.1B
Viatris (VTRS)
$15.6B
Avantor (AVTR)
$13.4B
Revvity (RVTY)
$13.4B
CochLear (CHEOY)
$12.8B
BioMerieux (BMXMF)
$12.7B
Solventum (SOLV)
$11.6B
Medpace Holdings (MEDP)
$9.8B
Doximity (DOCS)
$9.6B
Charles River Laboratories (CRL)
$9.5B
HealthEquity (HQY)
$9B
Sonic Healthcare (SKHHY)
$8.8B
Bausch + Lomb (BLCO)
$6.9B
Life Times (LTH)
$5.1B
Sotera Health (SHC)
$3.9B
Organon (OGN)
$3.8B
BrightSpring Health Services (BTSG)
$3.2B
Surgery Partners (SGRY)
$2.9B
PACS (PACS)
$2.6B
Concentras Parent (CON)
$2.6B
Ardent Health Partners (ARDT)
$2.4B
Premier (PINC)
$2.1B
Alignment Healthcare (ALHC)
$2.1B
Ryman Healthcare (RYHTY)
$2B
GeneDx Holdings (WGS)
$2B
GoodRx Holdings (GDRX)
$1.6B